Cervical Cancer Treatment Market

SKU: DMPH1068 | Last Updated On: Oct 19 2022 | Available Formats

> Cervical Cancer Treatment Market Expected to reach a high CAGR 5% By 2029:

Cervical Cancer Treatment Market is segmented By Type of Cancer (Squamous Cell Carcinoma, Adenocarcinoma, Adenosquamous Carcinoma), By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, Combined Therapy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Cervical Cancer Treatment Market size is projected to reach USD billion by 2029, with growth at a CAGR of 5% during the forecasting period (2022-2029). The cervix is the lower part of the uterus that connects to the vagina. Cervical cancer begins in the cells of the cervix. Most cervical malignancies are caused by strains of the sexually transmitted pathogen, Human Papillomavirus (HPV). When healthy cells mutate, the illness begins, resulting in uncontrolled cell growth. These cells form a tumor, which spreads to the surrounding tissues. Cervical cancers are divided into squamous cell carcinomas, adenocarcinomas, and adenosquamous carcinomas. Adenocarcinomas develop from gland cells, whereas squamous cell carcinomas develop from ectocervical cells. Cancer cells are supposed to mimic squamous cells under the microscope. In adenosquamous carcinomas, squamous cell carcinomas and adenocarcinomas coexist. Cryosurgery, laser surgery, simple hysterectomy, radical hysterectomy, and trachelectomy are all treatments for cervical cancer. Cystoscopy, proctoscopy, anesthesia, and imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), intravenous urography, and Positron Emission Tomography are used to identify cervical cancer (PET scan).

As per DataM Intelligence, Cervical Cancer Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Cervical Cancer Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Cervical Cancer Treatment Market in the United States and Canada produces the utmost share. Whereas the European Cervical Cancer Treatment Market is projected to continue its presence globally during the period of 2022- 2029.

Cervical Cancer Treatment Market Scope



Market CAGR


Segments Covered

By Type, By Treatment, By End use, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Market Dynamics

The market is driven by increased prevalence of cervical cancer, proactive government initiatives, awareness among people, new advancements in targeted therapies, and a strong pipeline of drugs.

Increasing FDA approvals for cervical cancer drugs is expected to drive market growth.

On September 20, 2021, the Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy. On October 13, 2021, Merck announced that the U.S. Food and Drug Administration (FDA) had approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1)as determined by an FDA-approved test. The approval is based on Phase 3 KEYNOTE-826 trial evaluating KEYTRUDA plus chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) to the same chemotherapy regimens, with or without bevacizumab. Moreover, Seven UN agencies under the United Nations Task Force on non-communicable diseases have established a Joint Programme to prevent and control cervical cancer to provide global leadership and technical assistance to support governments and partners in building and sustaining programs. Thus, from the above statements, the market is expected to drive in the forecast period.


High cost of treatment and adverse effects associated with cancer therapy, less number of targeted drugs with improved clinical profile at reduced costs, and lack of awareness of cancer treatment in developing countries are going to restrain the market in the forecast period.

Industry Analysis

The cervical cancer treatment market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in the cervical cancer treatment market.

Chemotherapy uses anti-cancer drugs injected into a vein or given by mouth. These drugs enter the bloodstream and can reach all body areas, making this treatment useful for killing cancer cells in most body parts. For some stages of cervical cancer, the preferred treatment is radiation and chemo, called concurrent chemoradiation. The chemo helps the radiation work better. The chemo drugs most often used to treat advanced cervical cancer includes Cisplatin, Carboplatin, Paclitaxel (Taxol), Topotecan, and Gemcitabine (Gemzar). Therefore, it has increased the demand for chemotherapy drugs. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region is expected to hold the largest market share in the global cervical cancer treatment market.

North America was the dominant region in the global cervical cancer treatment market and is expected to continue its dominance over the forecast period. This growth is attributed to a growing number of patients, increasing market penetration of drugs, and easy accessibility to advanced treatments. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths in the United States. In contrast, in 2022, about 14,100 new cases of invasive cervical cancer will be diagnosed, and about 4,280 women will die from cervical cancer. Therefore, it has increased the demand for cervical cancer treatment in the region.

Moreover, on September 20, 2021, Seagen Inc. and Genmab A/S granted the U.S. Food and Drug Administration (FDA) approval to TIVDAK (tisotumab vedotin-tftv), the first and only approved antibody-drug conjugate (ADC) for the treatment of adult patients with recurrent or metastatic cervical cancer who have disease progression during or after chemotherapy. TIVDAK was authorized under the FDA's Accelerated Approval Program based on tumor response and response durability. Continued approval may rely on verifying and describing clinical benefits in confirmatory trials.

Competitive Landscape

Major key players in the cervical cancer treatment market are F. Hoffmann-LA Roche AG, Merck & Co., Inc., GlaxoSmithKline PLC, Allergan PLC, Pfizer, Inc., Biocon Ltd., Bristol-Myers Squibb Company, AstraZeneca PLC, CooperSurgical, Inc., Ethicon, Inc., Eli Lilly & Co., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc.

Pfizer, Inc.:


Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

­Product Portfolio:

ZIRABEV (bevacizumab-bvzr): Zirabev has been approved for a number of cancer types and stages, in some cases as a single therapy, and in some cases in combination with other therapies.

Zirabev is approved for:

Colorectal cancer

Non-small cell lung cancer


Kidney cancer

Cervical cancer

Ovarian cancer

The global cervical cancer treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Trending Topics

Smart Healthcare Products Market

Patient Registry Software Market

Adhesive Bandages Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!